The patient’s thyroid status may also influence treatment efficacy and safety, as hypothyroidism is associated with elevated endostatin levels and hyperthyroidism is associated with reduced endostatin levels, each of which modifies angiogenic regulation. Here, COL18A1 is linked to hypothyroidism.